Acumen Pharmaceuticals Inc (ABOS) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Acumen Pharmaceuticals Inc   (NASDAQ: ABOS)


Acumen Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Acumen Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Acumen Pharmaceuticals Inc recorded a cumulative net loss of $-105 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -73.44%.

However, within the Healthcare sector 697 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4173, from total ROA ranking in the first quarter of 2026 at 4847.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 0.5 % -35.05 % -48.66 % -46.65 % -40.61 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -105 -113 -121 -133 -137
Return On Assets (TTM) -73.44 % -79.32 % -75.44 % -70.2 % -61.81 %
ABOS's Total Ranking # 4173 # 4847 # 4208 # 4202 # 4101
Total Assets (TTM) in million 173 134 123 143 172
Seq. Total Assets Change 29.51 % 8.79 % -13.86 % -17.19 % -16.3 %
Seq. Net Income Change - - - - -

ABOS's 5 Years Annual ROA >> Back to ABOS Management Effectiveness >> Compare ABOS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 108
Sector # 698
Overall # 4149

Return On Assets Statistics
High Average Low
-14.06 %
-39.27 %
-81.64 %
(Jun 30 2022)   (Jun 30 2026)





Financial Statements
Acumen Pharmaceuticals Inc 's Assets $ 173 million ABOS's Balance sheet
Acumen Pharmaceuticals Inc 's Income $ -33 million Quarterly ABOS's Income Statement
ABOS's Income by Division See ABOS's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -48.66 % -23.1 % 57.69 % -14.33 % -
Total Assets in million 123 239 311 197 230
Y / Y Net Income Change - - - - -
Net Income in million -121 -102 -52 -43 -101
Annual Return On Assets -98.78 % -42.77 % -16.83 % -21.72 % -43.68 %

ABOS's 5 Years Annual ROA >> Back to ABOS Management Effectiveness >> Compare ABOS ROA to its Competitors



More Return On Assets Ratios
ABOS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ABOS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ABOS's Competitors
Subscribers only: Roa for Acumen Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ABOS's Customers

You may also want to know
ABOS's Roi ABOS's Inventory Turnover Ratio ABOS's Growth Rates ABOS's Dividend Comparisons
ABOS's Profitability Ratios ABOS's Asset Turnover Ratio ABOS's Dividend Growth
ABOS's Roe ABOS's Valuation Ratios ABOS's Financial Strength Ratios ABOS's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-03T23:28:54+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.